The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
Open Access
- 1 July 2011
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 121 (7), 2723-2735
- https://doi.org/10.1172/jci44745
Abstract
Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display variable sensitivity to therapeutics and may play different roles in progression. We previously characterized 2 cell populations in human breast tumors with distinct properties: CD44+CD24– cells that have stem cell-like characteristics, and CD44–CD24+ cells that resemble more differentiated breast cancer cells. Here we identified 15 genes required for cell growth or proliferation in CD44+CD24– human breast cancer cells in a large-scale loss-of-function screen and found that inhibition of several of these (IL6, PTGIS, HAS1, CXCL3, and PFKFB3) reduced Stat3 activation. We found that the IL-6/JAK2/Stat3 pathway was preferentially active in CD44+CD24– breast cancer cells compared with other tumor cell types, and inhibition of JAK2 decreased their number and blocked growth of xenografts. Our results highlight the differences between distinct breast cancer cell types and identify targets such as JAK2 and Stat3 that may lead to more specific and effective breast cancer therapies.Keywords
This publication has 63 references indexed in Scilit:
- An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell TransformationCell, 2009
- IKK/NF‐κB and STAT3 pathways: central signalling hubs in inflammation‐mediated tumour promotion and metastasisEMBO Reports, 2009
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresProceedings of the National Academy of Sciences of the United States of America, 2009
- The Increasing Complexity of the Cancer Stem Cell ParadigmScience, 2009
- STAT3 as a central regulator of tumor metastases.Current Molecular Medicine, 2009
- CXCR2 antagonists for the treatment of pulmonary diseasePharmacology & Therapeutics, 2009
- Purification and characterization of recombinant human prostacyclin synthase.The Journal of Biochemistry, 2004
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002
- Autocrine-mediated Activation of STAT3 Correlates with Cell Proliferation in Breast Carcinoma LinesOnline Journal of Public Health Informatics, 2002